Journal
CURRENT DRUG TARGETS
Volume 15, Issue 2, Pages 151-155Publisher
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/13894501113149990199
Keywords
Cadila; lipaglyn; saroglitazar; diabetes; PPAR agonist; NCE; approval
Categories
Ask authors/readers for more resources
The new chemical entity ( NCE) has been knocked as novel antidiabetic agent, e.g. Saroglitazar. Saroglitazar is a drug for the treatment of Type II diabetes. Saroglitazar is marketed under the trade name Lipaglyn, developed by the Zydus Cadila. Lipaglyn is the first indigenously developed NCE by any Indian pharmaceutical company, ever. Lipaglyn has been approved for the treatment of Type II diabetes by the Drug Controller General of India in June 2013. Lipaglyn is indicated for the patients suffering from diabetes dyslipidemia. It also provides the option of a once-daily oral therapy. Saroglitazar regulates the lipid parameters as well as glycemic control. The present article describes Saroglitazar with its chemical synthesis and patent status with its summary of clinical studies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available